Item 1.01. Entry into a Material Definitive Agreement.
On April 19, 2023, Gamida Cell Ltd. entered into an underwriting
agreement with Piper Sandler & Co., as
representative of the several. | April 21, 2023
Gamida Cell Ltd. , a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the launch of a follow-on public offering of its ordinary shares and accompanying warrants. | April 18, 2023
Gamida Cell Ltd. announced that the U.S. Food and Drug Administration has approved Gamida Cell s allogeneic cell therapy, Omisirge® , for use in adult and pediatric patients 12 years and. | April 18, 2023
By Josh Beckerman Gamida Cell Ltd. shares rose 34% to $1.08 Monday after the U.S. Food and Drug Administration approved the Boston-based biotechnology company s Omisirge cell therapy for. | April 17, 2023